Literature DB >> 23912520

[The effect of ivermectin on geohelminth frequency (i.e. as used in the onchocerciasis control program in Colombia)].

Angélica Knudson1, Yoseth Ariza, Myriam C López, Oscar S Fajardo, Patricia Reyes, Ligia I Moncada, Sofía Duque, Carlos A Álvarez, Rubén S Nicholls.   

Abstract

OBJECTIVE: Evaluating the effect of ivermectin on soil-transmitted helminthes (STH) infection frequency in a Colombian population included in the Onchocerciasis Elimination Program for the Americas (OEPA).
METHODS: This was an impact evaluation study which adopted a longitudinal approach using the population of Naicioná (1996) as baseline for comparison to people from the same population as controls (2008). The cross-sectional approach involved comparing the reference population of Naicioná (2008) to the population of Dos Quebradas (2008) used as controls. Fecal samples were processed by a modified Ritchie-Frick method.
RESULTS: Ascaris lumbricoides was the most frequently found parasite in Naicioná (60/121; 49.6 %: 37.8-63.895%CI) and in Dos Quebradas (36/76; 47.4 %: 33.2-65.6 95 % CI). Ivermectin's main effect on the population aged over 5 years was a decreased risk of Trichiuris trichiura infection in both longitudinal assessment (86 % reduction: 74-93 95 % CI) and cross-sectional assessment (63 %:24-82 95 % CI). A 93 % reduction (45-99 95 % CI) in Strongyloides stercoralis frequency was found in longitudinal assessment, compared to 85 % in cross-sectional assessment (-031-99 95 % CI).
CONCLUSIONS: Ivermectin use in the OEPA is not sufficient for STH morbidity control. Integrated programs including education and basic sanitation are required.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23912520

Source DB:  PubMed          Journal:  Rev Salud Publica (Bogota)        ISSN: 0124-0064


  3 in total

1.  Ivermectin susceptibility, sporontocidal effect, and inhibition of time to re-feed in the Amazonian malaria vector Anopheles darlingi.

Authors:  Kevin C Kobylinski; Karín S Escobedo-Vargas; Victor M López-Sifuentes; Salomón Durand; Edward S Smith; G Christian Baldeviano; Robert V Gerbasi; Sara-Blythe Ballard; Craig A Stoops; Gissella M Vásquez
Journal:  Malar J       Date:  2017-11-21       Impact factor: 2.979

2.  A systematic review and an individual patient data meta-analysis of ivermectin use in children weighing less than fifteen kilograms: Is it time to reconsider the current contraindication?

Authors:  Podjanee Jittamala; Wuelton Monteiro; Menno R Smit; Belen Pedrique; Sabine Specht; Carlos J Chaccour; Céline Dard; Pascal Del Giudice; Virak Khieu; Annabel Maruani; Virgilio E Failoc-Rojas; Marimar Sáez-de-Ocariz; Antoni Soriano-Arandes; Jaime Piquero-Casals; Anne Faisant; Marie-Pierre Brenier-Pinchart; David Wimmersberger; Jean T Coulibaly; Jennifer Keiser; Franck Boralevi; Oliver Sokana; Michael Marks; Daniel Engelman; Lucia Romani; Andrew C Steer; Lorenz von Seidlein; Nicholas J White; Eli Harriss; Kasia Stepniewska; Georgina S Humphreys; Kalynn Kennon; Philippe J Guerin; Kevin C Kobylinski
Journal:  PLoS Negl Trop Dis       Date:  2021-03-17

3.  Mass Administration of Ivermectin for the Elimination of Onchocerciasis Significantly Reduced and Maintained Low the Prevalence of Strongyloides stercoralis in Esmeraldas, Ecuador.

Authors:  Mariella Anselmi; Dora Buonfrate; Angel Guevara Espinoza; Rosanna Prandi; Monica Marquez; Maria Gobbo; Antonio Montresor; Marco Albonico; Marcia Racines Orbe; Juan Martin Moreira; Zeno Bisoffi
Journal:  PLoS Negl Trop Dis       Date:  2015-11-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.